Clinical Trials Logo

Primary Myelofibrosis clinical trials

View clinical trials related to Primary Myelofibrosis.

Filter by:

NCT ID: NCT05123365 Recruiting - Myelofibrosis Clinical Trials

An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms

Start date: January 3, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I/II study evaluating the optimal dose of N-acetylcysteine (N-AC) in patients with myeloproliferative neoplasms (MPN).

NCT ID: NCT05044026 Completed - Clinical trials for Primary Myelofibrosis

A Prospective, Two-arm, Non-interventional Study of JAKAVI® (Ruxolitinib) in Patients With Myelofibrosis

JAKoMo
Start date: September 20, 2012
Phase:
Study type: Observational

This was a prospective, two-arm, non-interventional study of JAKAVI® (Ruxolitinib) in patients with myelofibrosis

NCT ID: NCT05037760 Recruiting - Myelofibrosis Clinical Trials

Study to Evaluate KER-050 as a Monotherapy or in Combination With Ruxolitinib in Myelofibrosis

Start date: December 16, 2021
Phase: Phase 2
Study type: Interventional

This is a Phase 2, multicenter, open-label study to evaluate the safety and efficacy of KER-050 as monotherapy or in combination with ruxolitinib in participants with Myelofibrosis.

NCT ID: NCT05020652 Recruiting - Clinical trials for Moderate and High Risk Myelofibrosis

A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis

Start date: November 11, 2021
Phase: Phase 2
Study type: Interventional

Q05105 tablet is a Janus kinase 2 (JAK2) inhibitor, which can be used to treat JAK2 target related diseases, such as moderate or high-risk multiple myelofibrosis

NCT ID: NCT04988815 Recruiting - Myelofibrosis Clinical Trials

Ropeginterferon Alfa 2b for Early Myelofibrosis

Start date: September 1, 2021
Phase: Phase 2
Study type: Interventional

This is a multi-centre phase 2 open-label prospective study designed to assess the efficacy and safety of ropeg patients with pre-fibrotic primary myelofibrosis or DIPSS low/intermediate-1 risk myelofibrosis after 24 months of treatment.

NCT ID: NCT04942080 Recruiting - Clinical trials for Myeloproliferative Neoplasm

Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI)

CALRSUIVI
Start date: October 28, 2021
Phase: N/A
Study type: Interventional

Prospective study to evaluate the relevance of CALR allele burden monitoring as a molecular marker of disease progression.

NCT ID: NCT04896112 Withdrawn - Clinical trials for Acute Myeloid Leukemia

A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia

Start date: April 8, 2021
Phase: Phase 1
Study type: Interventional

This multicenter, open-label, phase 1 study designed to evaluate safety and tolerability of multi-kinase inhibitor LNK01002 in patients with primary myelofibrosis (PMF), or MF due to polycythemia vera (PV-MF), or essential thrombocythemia (ET-MF), polycythemia vera (PV), or with acute myeloid leukemia (AML).

NCT ID: NCT04884191 Completed - Clinical trials for Primary Myelofibrosis

Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib

Start date: July 31, 2017
Phase: Phase 2
Study type: Interventional

This was an open-label, randomized, dose-finding study in patients with primary or secondary MF (Dynamic International Prognostic Scoring System [DIPSS] risk score of Intermediate-1 to High-Risk) who were previously treated with ruxolitinib. The study was designed to support a pacritinib dosage selection decision with evaluation of 3 dosages.

NCT ID: NCT04878003 Recruiting - Clinical trials for Primary Myelofibrosis (PMF)

Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis

Start date: April 13, 2021
Phase: Phase 2
Study type: Interventional

This study evaluates either KRT-232 or TL-895 in treatment naïve patients with myelofibrosis (MF) The study will be conducted in 2 stages. Stage 1 will evaluate safety, tolerability, and efficacy of either KRT-232 (Arm 1) or TL-895 (Arm 2) in treatment naïve patients. Stage 2 will expand enrollment in Arm 1 and/or Arm 2 if expansion criteria is met.

NCT ID: NCT04866056 Terminated - Clinical trials for Myelodysplastic Syndromes

Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.

Start date: September 30, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies how well Jaktinib and azacytidine work in treating patients with myelodysplastic syndromes with myelofibrosis or myelodysplastic syndrome/myeloproliferative neoplasm with myelofibrosis. Giving Jaktinib and azacytidine may be an effective treatment for myelodysplastic syndromes with myelofibrosis or myelodysplastic syndrome/myeloproliferative neoplasm with myelofibrosis.